Neal Shore, MD, FACS, shares his final thoughts on the current landscape of clinical trials for both non-muscle-invasive bladder cancer and muscle-invasive bladder cancer, providing insights into the ...
Neal Shore, MD, FACS, discuss the key efficacy outcomes reported for nadofaragene firadenovec (ADSTILADRIN) in the phase 3 trial for patients with Bacillus Calmette-Guérin (BCG)-unresponsive ...
Neal Shore, M.D., FACS is the medical director of the Carolina Urologic Research Center and is an internationally recognized expert in Urologic Oncology. Dr. Shore is a practicing Urologist at the ...
(MENAFN- EIN Presswire) EINPresswire/ -- Alessa Therapeutics (“Alessa”), a clinical-stage biopharmaceutical company advancing novel localized drug delivery technology for the treatment of early-stage ...
Stark Law and anti-kickback statutes create obstacles to developing alternative payment models suited for independent specialty practices, Large Urology Group Practice Association President Neal Shore ...
Bone metastases often create significant problems for patients with advanced prostate cancer, according to Neal Shore. Bone metastases are a common and problematic situation that many patients with ...
SYDNEY, May 26, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in ...
SAN CARLOS, CA, UNITED STATES, May 22, 2026 /EINPresswire.com/ — Alessa Therapeutics (“Alessa”), a clinical-stage biopharmaceutical company advancing novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results